Insider Trading Alert - KND, ALQA And OSK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 4, 2015, 82 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1.50 to $744,000,000,054.72.

Highlighted Stocks Traded by Insiders:

Kindred Healthcare (KND) - FREE Research Report

Breier Benjamin A, who is President & CEO at Kindred Healthcare, sold 5,400 shares at $23.38 on May 4, 2015. Following this transaction, the President & CEO owned 573,850 shares meaning that the stake was reduced by 0.93% with the 5,400-share transaction.

The shares most recently traded at $23.64, up $0.26, or 1.11% since the insider transaction. Historical insider transactions for Kindred Healthcare go as follows:

  • 4-Week # shares sold: 9,810
  • 12-Week # shares sold: 10,191
  • 24-Week # shares bought: 8,000
  • 24-Week # shares sold: 10,191

The average volume for Kindred Healthcare has been 1.2 million shares per day over the past 30 days. Kindred Healthcare has a market cap of $2.0 billion and is part of the health care sector and health services industry. Shares are up 33% year-to-date as of the close of trading on Monday.

Kindred Healthcare, Inc. provides healthcare services in the United States. It operates in four divisions: Hospital, Nursing Center, Rehabilitation, and Care Management. The stock currently has a dividend yield of 1.99%. Currently, there are 3 analysts who rate Kindred Healthcare a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KND - FREE

TheStreet Quant Ratings rates Kindred Healthcare as a hold. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, generally higher debt management risk and poor profit margins. Get the full Kindred Healthcare Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alliqua BioMedical (ALQA) - FREE Research Report

Celgene Corp /De/, who is 10% Owner at Alliqua BioMedical, bought 659,340 shares at $4.55 on May 4, 2015. Following this transaction, the 10% Owner owned 3.0 million shares meaning that the stake was boosted by 27.62% with the 659,340-share transaction.

The shares most recently traded at $4.78, up $0.23, or 4.81% since the insider transaction. Historical insider transactions for Alliqua BioMedical go as follows:

  • 4-Week # shares bought: 714,286
  • 12-Week # shares bought: 714,286
  • 24-Week # shares bought: 2,000

The average volume for Alliqua BioMedical has been 82,300 shares per day over the past 30 days. Alliqua BioMedical has a market cap of $80.7 million and is part of the health care sector and drugs industry. Shares are down 9.43% year-to-date as of the close of trading on Monday.

Alliqua BioMedical, Inc. provides wound care solutions. Currently, there are 4 analysts who rate Alliqua BioMedical a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALQA - FREE

TheStreet Quant Ratings rates Alliqua BioMedical as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Alliqua BioMedical Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Oshkosh (OSK) - FREE Research Report

Urias John M., who is EVP and Pres., Defense Segment at Oshkosh, sold 6,100 shares at $53.85 on May 4, 2015. Following this transaction, the EVP and Pres., Defense Segment owned 27,822 shares meaning that the stake was reduced by 17.98% with the 6,100-share transaction.

The shares most recently traded at $53.36, down $0.49, or 0.92% since the insider transaction. Historical insider transactions for Oshkosh go as follows:

  • 4-Week # shares sold: 4,433
  • 12-Week # shares sold: 4,433
  • 24-Week # shares sold: 18,933

The average volume for Oshkosh has been 808,800 shares per day over the past 30 days. Oshkosh has a market cap of $4.3 billion and is part of the consumer goods sector and automotive industry. Shares are up 12.66% year-to-date as of the close of trading on Monday.

Oshkosh Corporation designs, manufactures, and markets specialty vehicles and vehicle bodies worldwide. Its Access Equipment segment offers aerial work platforms and telehandlers used in construction, agricultural, industrial, institutional, and general maintenance applications. The stock currently has a dividend yield of 1.24%. The company has a P/E ratio of 16.8. Currently, there are 7 analysts who rate Oshkosh a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on OSK - FREE

TheStreet Quant Ratings rates Oshkosh as a buy. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Oshkosh Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%